Method of treating Parkinson's disease

• US 10,639,316 B1
• Filed: 05/30/2019
• Issued: 05/05/2020
• Est. Priority Date: 04/30/2019
• Status: Active Grant

• Current Assignee: LA Pharmatech Inc.
• Original Assignee: LA Pharmatech Inc.
• Inventors: Wang, Jianmin, Cui, Geping
• Primary Examiner(s): Anderson, James D.
• Application Number:
  US16/426,121
• Time in Patent Office: 341 Days
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine is disclosed.

Claims

1. A method comprising orally administering an oral formulation to a patient having Parkinson'"'"'s disease, daily and for a period of at least six weeks, the oral formulation comprising about 12 mg to about 40 mg azelastine or a pharmaceutically acceptable salt of azelastine, thereby improving the patient'"'"'s quality of life as demonstrated by the patient requiring less need for support with the patient'"'"'s activities of daily living.

2. The method of claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

3. The method of claim 1, wherein the oral formulation comprises about 12 mg to about 20 mg of the azelastine or the pharmaceutically acceptable salt of azelastine.

4. The method of claim 1, wherein the oral formulation is a solid form or a liquid form.

5. The method of claim 1, wherein the oral formulation comprises 16 mg to 20 mg azelastine or a pharmaceutically acceptable salt of azelastine.

6. A method comprising orally administering an oral formulation to a patient having Parkinson'"'"'s disease, the oral formulation comprising about 12 mg to 40 mg azelastine or a pharmaceutically acceptable salt of azelastine, whereby the oral formulation is administered daily and for a period of time to improve one or more symptoms of the patient'"'"'s Alzheimer'"'"'s disease as measured by Mini-Mental State Examination (MMSE).

7. The method of claim 6, wherein the oral formulation is administered for a period of time to improve one or more symptoms of the patient'"'"'s Parkinson'"'"'s disease as measured by Neuropsychiatric Inventory (NPI) and Activities of Daily Living (ADL).

8. The method of claim 6, wherein the oral formulation comprises about 12 mg to about 20 mg of the azelastine or the pharmaceutically acceptable salt of azelastine.

9. The method of claim 7, wherein the oral formulation comprises about 12 mg to about 20 mg of the azelastine or the pharmaceutically acceptable salt of azelastine.